Nuwellis (NUWE) to Release Quarterly Earnings on Thursday

Nuwellis (NASDAQ:NUWE) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Nuwellis to announce earnings of ($23.80) per share and revenue of $2.4150 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:00 AM ET.

Nuwellis (NASDAQ:NUWE) last released its earnings results on Tuesday, May 12th. The company reported ($73.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($35.00) by ($38.15). The firm had revenue of $2.40 million during the quarter, compared to analysts’ expectations of $2.09 million. Nuwellis had a negative net margin of 214.90% and a negative return on equity of 32,351.83%.

Nuwellis Price Performance

Shares of NASDAQ NUWE opened at $1.42 on Tuesday. The company has a market cap of $2.64 million, a PE ratio of -0.00 and a beta of 0.31. Nuwellis has a 12 month low of $1.34 and a 12 month high of $235.20. The company has a 50-day simple moving average of $4.14 and a 200-day simple moving average of $36.02.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NUWE. Weiss Ratings restated a “sell (e+)” rating on shares of Nuwellis in a research report on Wednesday, June 24th. Wall Street Zen upgraded Nuwellis to a “hold” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Nuwellis

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid?overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low?shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.